Abstract

Corruption in the health sector is unique because it includes abuse by public officials and unscrupulous behavior by other actors (drug manufacturers, health professionals, patients, etc.). The urgency of solving the scientific problem lies in the fact that financial relations in the medical field arise between a wide range of persons who can act as initiators of corruption decisions and/or their executors. The study’s main goal is to analyze the forms of corruption in the healthcare system and their consequences for society, as well as to assess the degree of interrelationship between the level of corruption and indicators of financial support in the healthcare sector. The methods of structural and comparative bibliometric analysis and correlation analysis became the methodical tools of the conducted research. The object of research is 140 countries in the world. The conducted bibliometric analysis testified to the permanent growth of the study of the issue of corruption in medicine in the scientific environment. Scientists from the United States, United Kingdom, and Germany have implemented the largest number of works on a certain topic. The conducted correlation analysis also empirically confirmed that an increase in the level of corruption in the country leads to an increase in the share of household expenses for financing their own medical needs. The article founds that the population in countries with a low level of corruption (the corruption promotion index is closer to 100) has a higher level of provision of vital medical services (reproductive health, health of women, newborns, and children, infectious diseases, non-infectious diseases and opportunities provision of services and access to them). Countries with a high level of anti-corruption and coverage of medical services include Finland, Sweden, Germany, and Great Britain. The results of the research can be useful for state regulatory bodies, specialized organizations in the field of health care, as well as public organizations.

Keywords: bribery, corruption, coverage of medical services, health care, pharmaceuticals.

JEL Classification: D73, H15, I15.

Cite as: Bozhenko, V. (2022). Tackling corruption in the health sector. Health Economics and Management Review, 3(3), 32-39. https://doi.org/10.21272/hem.2022.3-03

This work is licensed under a Creative Commons Attribution 4.0 International License

References

1. Achim, M. V., Vaidean, V. L., & Borlea, S. N. (2020). Corruption and health outcomes within an economic and cultural framework. European Journal of Health Economics, 21(2), 195–207. [Google Scholar] [CrossRef]
2. Bozhenko, V. (2021). Enhancing Business Integrity as a Mechanism for Combating Corruption and Shadow Schemes in the Country. Business Ethics and Leadership, 5(3), 97-101. [Google Scholar] [CrossRef]
3. Cabelkova, I., Tvaronaviciene, M., & Strielkowski, W. (2021). Innovations in achieving sustainable economic performance under income inequality. Marketing and Management of Innovations, 2, 146-154. [Google Scholar] [CrossRef]
4. Campos, J. E., & Pradhan, S. (Eds.). (2007). The many faces of corruption: tracking vulnerabilities at the sector level. World Bank Publications. [Google Scholar]
5. Delavallade, C. (2006). Corruption and distribution of public spending in developing countries. Journal of Economics and Finance, 30(2), 222–239. [Google Scholar] [CrossRef]
6. Gagnon, M. A., & Lexchin, J. (2008). The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine, 5(1), 0029–0033. [Google Scholar] [CrossRef]
7. Gagnon, M. A. (2013). Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health’. Journal of Law, Medicine & Ethics, 41, 3, 572. [Google Scholar] [CrossRef]
8. GRECO. (2020). Corruption Risks and Useful Legal References in the context of COVID-19. URL. Retrieved from [Link]
9. Hanf, M., Van-Melle, A., Fraisse, F., Roger, A., Carme, B., & Nacher, M. (2011). Corruption kills: estimating the global impact of corruption on children deaths. PLoS One, 6(11), e26990. [Google Scholar] [CrossRef]
10. Hussmann, K. (2020). Health sector corruption. Practical recommendations for donors. CHR. Michelsen Institute. U4 Issue 2020: 10. Retrieved from [Link]
11. Juarez-Garcia, M.I. (2020). Personal Corruption & Corrupting Laws: Montesquieu’s Twofold Theory of Corruption. Business Ethics and Leadership, 4(4), 76-84. [Google Scholar] [CrossRef]
12. Kouassi, K. B. (2018). Public Spending and Economic Growth in Developing Countries: a Synthesis. Financial Markets, Institutions and Risks, 2(2), 22-30. [Google Scholar]
13. Li, Q., An, L., Xu, J., & Baliamoune-Lutz, M. (2018). Corruption costs lives: evidence from a cross-country study. European Journal of Health Economics, 19(1), 153–165. [Google Scholar] [CrossRef]
14. Liaropoulos, L., Siskou, O., Kaitelidou, D., Theodorou, M., & Katostaras, T. (2008). Informal payments in public hospitals in Greece. Health Policy, 87(1), 72–81. [Google Scholar] [CrossRef]
15. Light, D. W., Lexchin, J., & Darrow, J. J. (2013). Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. Journal of Law, Medicine and Ethics, 41(3), 590–600. [Google Scholar] [CrossRef]
16. More, I., & Aye, G. C. (2017). Effect of social infrastructure investment on economic growth and inequality in South Africa: a SEM approach. International Journal of Economics and Business Research, 13(2), 95-109. [Google Scholar]
17. Mrabet, S., Benachenhou, S.M., Khalil, A. (2022). Measuring the Effect of Healthcare Service Quality Dimensions on Patient’s Satisfaction in The Algerian Private Sector. SocioEconomic Challenges, 6(1), 100-112. [Google Scholar] [CrossRef]
18. Mynenko, S. (2022). The Impact of Digitalization on the Transparency of Public Authorities. Business Ethics and Leadership, 6(2), 103-115. [Google Scholar] [CrossRef]
19. OECD (2011). Health at a glance 2011: OECD indicators. Organisation for Economic Cooperation and Development Publishing. Retrieved from [Link]
20. OECD (2020). Public Integrity for an Effective COVID-19 Response and Recovery. Retrieved from [Link]
21. Ozawa, S., Evans, D. R., Bessias, S., Haynie, D. G., Yemeke, T. T., Laing, S. K., & Herrington, J. E. (2018). Prevalence and estimated economic burden of substandard and falsified medicines in low-and middle-income countries: a systematic review and meta-analysis. JAMA network open, 1(4), e181662-e181662. [Google Scholar]
22. Palienko, M., & Lyulyov, O. (2018). The impact of social factors on macroeconomic stability: empirical evidence for Ukraine and European Union countries. SocioEconomic Challenges, 2(1), 103-116. [Google Scholar]
23. RCC. (2018). Checklists on Corruption Risks in the Healthcare Sector. Retrieved from [Link]
24. Rekunenko, I., Boiko, A., Kramarenko, O., & Khan, B. (2022). Data Management in Healthcare Research as a Guarantee of its Quality. Health Economics and Management Review, 3(2), 36-43. [Google Scholar] [CrossRef]
25. Saher, L., Vakulenko, I., Shevchenko, K., Bondarenko, Y., & Lyulyov, O. (2022). Bibliometric and Retrospective Analysis on Economic Behavior for Inclusive Growth. Financial Markets, Institutions and Risks, 6(2), 102-111. [Google Scholar] [CrossRef]
26. Steingruber, S., & Gadanya, M. (2021). Weak links: How corruption affects the quality and integrity of medical products and impacts on the Covid-19 response. U4 Issue, 15. Retrieved from [Link]
27. Telizhenko, O., Halynska, Yu., Baistriuchenko, N., Potseluiev, V., & Demchuk, K. (2022). Organizational and Economic Factors of Health System Optimization. Health Economics and Management Review, 3(2), 26-35. [Google Scholar] [CrossRef]
28. Transparency International. (2006). Global Corruption Report 2006. London and Ann Arbor: Pluto Press, 2006. Retrieved from [Link]
29. Transparency International. (2021). Global Corruption Barometer European Union 2021. Citizens’ views and experiences of corruption. Retrieved from [Link]
30. UN Human Rights. Special Rapporteur on the right to health. Retrieved from [Link]
31. Vasylyev, Yu., Savchenko, I., Us, Ya., & Veckalne, R. (2021). Generating Confidence in the Healthcare System through Information Activities of Healthcare Institutions. Health Economics and Management Review, 2(4), 38-51. [Google Scholar] [CrossRef]
32. Vincke, P., & Cylus J. (2011). Health care fraud and corruption in Europe. Retrieved from [Link]
33. Vysochyna, A., Semenov, V., & Kyrychenko, K. (2021). Marketing and management of innovations in public governance as core determinants of trust Marketing and Management of Innovations, 2, 204-212. [Google Scholar] [CrossRef]
34. WHO. (1998). Health Promotion Glossary. Retrieved from [Link]
35. World Bank. (2000). Anti-Corruption Policies in a largely corruption-free environment, anti-corruption and Program. Retrieved from [Link]